Diet boosts Crohn's drug in kids: new study hopes to cut meds
NCT ID NCT07314606
First seen Jan 04, 2026 · Last updated Jun 16, 2026 · Updated 24 times
Summary
This study tests whether adding a special diet (Crohn's Disease Exclusion Diet) to the standard drug infliximab helps children with Crohn's disease feel better and stay in remission longer. About 140 children starting infliximab will be randomly assigned to receive the diet plus drug or drug alone. The goal is to improve treatment response and reduce long-term medication needs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IBD-INFLAMMATORY BOWEL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of British Columbia
RECRUITINGVancouver, British Columbia, V5Z 4H4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.